Australia Cancer Supportive Care Drugs Market Size & Outlook
Australia cancer supportive care drugs market, 2018-2030 (US$M)
Related Markets
Australia cancer supportive care drugs market highlights
- The Australia cancer supportive care drugs market generated a revenue of USD 287.4 million in 2023 and is expected to reach USD 273.1 million by 2030.
- The Australia market is expected to grow at a CAGR of -0.7% from 2024 to 2030.
- In terms of segment, antiemetics was the largest revenue generating therapeutic class in 2023.
- NSAIDs and Others is the most lucrative therapeutic class segment registering the fastest growth during the forecast period.
Cancer supportive care drugs market data book summary
| Market revenue in 2023 | USD 287.4 million |
| Market revenue in 2030 | USD 273.1 million |
| Growth rate | -0.7% (CAGR from 2023 to 2030) |
| Largest segment | Antiemetics |
| Fastest growing segment | NSAIDs and Others |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDs and Others |
| Key market players worldwide | Amgen Inc, Merck & Co Inc, Johnson & Johnson, Heron Therapeutics Inc, Novartis AG ADR, GSK PLC, Roche Holding AG ADR, Helsinn Healthcare |
Other key industry trends
- In terms of revenue, Australia accounted for 2.2% of the global cancer supportive care drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan cancer supportive care drugs market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 346.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Supportive Care Drugs Market Scope
Cancer Supportive Care Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia cancer supportive care drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer supportive care drugs market will help companies and investors design strategic landscapes.
Antiemetics was the largest segment with a revenue share of 25.82% in 2023. Horizon Databook has segmented the Australia cancer supportive care drugs market based on g-csfs (granulocyte-colony stimulating factors), esas (erythropoiesis stimulating agents), antiemetics, bisphosphonates, opioids, nsaids and others covering the revenue growth of each sub-segment from 2018 to 2030.
Australia, with an age-standardized rate of 452.4 per 100,000 population, has one of the highest rates of cancers in the world, as per International Agency for Research on Cancer. In addition, Australia has one of the highest ASRs of Hodgkin’s lymphoma globally, with further growth projected in its rapidly increasing elderly population. Given this high prevalence of cancer, the country has focused on providing payment assistance for certain cancer therapeutics and related supportive care drugs.
In Australia, according to Cancer Council Australia, for cancer pain related supportive cancer care, the first line of treatment includes regular analgesia. Subsequently, the second line of therapy consists of antiemetic drugs. This recommendation varies with the type and stage of cancer. For instance, in advanced breast cancer, bisphosphonate drugs are recommended. However, in Australia, the healthcare system does not recommend opioids in cancer supportive care, owing to its addictiveness and side effects.
Reasons to subscribe to Australia cancer supportive care drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia cancer supportive care drugs market databook
-
Our clientele includes a mix of cancer supportive care drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia cancer supportive care drugs market , including forecasts for subscribers. This country databook contains high-level insights into Australia cancer supportive care drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia cancer supportive care drugs market size, by therapeutic class, 2018-2030 (US$M)
Australia Cancer Supportive Care Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
